Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: Implications for ocular angiogenesis

被引:129
作者
Duh, EJ
Yang, HS
Haller, JA
De Juan, E
Humayun, MS
Gehlbach, P
Melia, M
Pieramici, D
Harlan, JB
Campochiaro, PA
Zack, DJ
机构
[1] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA
[3] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21287 USA
关键词
D O I
10.1016/j.ajo.2003.11.015
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: Pigment epithelium,derived factor (PEDF) has been demonstrated to suppress ocular angiogenesis in several animal models. In this study, we sought to measure the levels of PEDF and vascular endothelial growth factor (VEGF) in the vitreous of patients with and without ocular neovascular disorders. DESIGN: Case-control study of patients undergoing intraocular surgery for a variety of neovascular and nonneovascular conditions. METHODS: Vitreous samples were collected from 65 eyes of 65 patients with no neovascular disorder (n = 24), choroidal neovascularization (n = 9), active proliferative diabetic retinopathy (n = 16), and inactive proliferative diabetic retinopathy (n = 16). The levels of VEGF and PEDF in these vitreous samples were determined by enzyme,linked immunosorbent assay. RESULTS: The VEGF levels were at or below the level of detectability in the reference and choroidal neovascularization groups. The VEGF levels were significantly elevated in both the active and inactive PDR groups, and significantly higher in the active PDR group as compared with the inactive PDR group. The PEDF levels, which were present at relatively high concentrations in all groups, were higher in patients with active PDR compared with the control and choroidal neovascularization groups. 0 CONCLUSIONS: High levels of immunoreactive PEDF are present in the vitreous of individuals with or without ocular neovascularization, but PEDF levels are significantly higher in patients with active PDR compared with patients with choroidal neovascularization or nonneovascular retinal diseases. Although these results do not preclude the possibility that endogenous PEDF helps to modulate ocular neovascularization, they do not support ischemia,induced downregulation of PEDF as a mechanism for such modulation. (C) 2004 by Elsevier Inc. All rights reserved.
引用
收藏
页码:668 / 674
页数:7
相关论文
共 45 条
[1]   INCREASED VASCULAR ENDOTHELIAL GROWTH-FACTOR LEVELS IN THE VITREOUS OF EYES WITH PROLIFERATIVE DIABETIC-RETINOPATHY [J].
ADAMIS, AP ;
MILLER, JW ;
BERNAL, MT ;
DAMICO, DJ ;
FOLKMAN, J ;
YEO, TK ;
YEO, KT .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 118 (04) :445-450
[2]   Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate [J].
Adamis, AP ;
Shima, DT ;
Tolentino, MJ ;
Gragoudas, ES ;
Ferrara, N ;
Folkman, J ;
DAmore, PA ;
Miller, JW .
ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (01) :66-71
[3]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[4]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[5]   Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents [J].
Auricchio, A ;
Behling, KC ;
Maguire, AM ;
O'Connor, EE ;
Bennett, J ;
Wilson, JM ;
Tolentino, MJ .
MOLECULAR THERAPY, 2002, 6 (04) :490-494
[6]   Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy [J].
Cantón, A ;
Burgos, R ;
Hernández, C ;
Mateo, C ;
Segura, RM ;
Mesa, J ;
Simó, R .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2000, 84 (07) :732-735
[7]   Pigment epithelium-derived factor: A potent inhibitor of angiogenesis [J].
Dawson, DW ;
Volpert, OV ;
Gillis, P ;
Crawford, SE ;
Xu, HJ ;
Benedict, W ;
Bouck, NP .
SCIENCE, 1999, 285 (5425) :245-248
[8]  
Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
[9]   CYTOKINES IN PROLIFERATIVE DIABETIC-RETINOPATHY AND PROLIFERATIVE VITREORETINOPATHY [J].
ELNER, SG ;
ELNER, VM ;
JAFFE, GJ ;
STUART, A ;
KUNKEL, SL ;
STRIETER, RM .
CURRENT EYE RESEARCH, 1995, 14 (11) :1045-1053
[10]   Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy [J].
Freyberger, H ;
Bröcker, M ;
Yakut, H ;
Hammer, J ;
Effert, R ;
Schifferdecker, E ;
Schatz, N ;
Derwahl, M .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2000, 108 (02) :106-109